LONDON, Aug. 28,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, today announced that it has
entered into a distribution agreement with a supplier of (RT) PCR
Mpox virus detection kits to commercialize them in 13 European
countries as well as members of the Gulf Cooperation Council
("GCC") including Bahrain,
Kuwait, Oman, Qatar,
Saudi Arabia, and the United Arab Emirates.
The RT PCR Mpox virus detection kits are CE-marked for sale in
Europe and also authorized by the
Medicines and Healthcare products Regulatory Agency (MHRA), the
product regulatory agency for the United
Kingdom. These tests perform with a sensitivity of
96.7% and specificity of 93.72%, with the ability to deliver
results in under 70 minutes.
"Mpox virus poses a serious threat, and we continue to be
committed to equipping healthcare professionals with the necessary
tools to diagnose and mitigate its spread," James Foster, CEO of Virax Biolabs. "Our
partnership with our suppliers, a leader in sales of diagnostic
reagents and equipment related to infectious pathogens, underscores
our commitment and enables us to reach at-risk communities across
major geographies."
Under the terms of the agreement, Virax is authorized to import,
sell and distribute Virax-branded Mpox virus Nucleic Acid Detection
Kits in European countries including the United Kingdom, France, Portugal, The
Netherlands, Belgium,
Sweden, Finland, Denmark, Norway, Germany, Spain, Switzerland, Austria, as well as the GCC set of
nations.
Potential interested parties in our Early Release Partnership
Program ("ERPP") for the Mpox RT-PCR Detection kits can contact our
sales representatives through our dedicated website
www.viraxclear.com.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-distribution-agreement-to-commercialize-mpox-formerly-monkeypox-virus-rt-pcr-detection-kits-in-europe-and-the-middle-east-302232129.html
SOURCE Virax Biolabs
